Billionaire Stanley Druckenmiller’s 2022 Portfolio: 5 Value Stock Picks

3. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Holders: 18

P/E Ratio as of May 18: 12.45

AbCellera Biologics Inc. (NASDAQ:ABCL) is based in Vancouver, Canada, operating an artificial intelligence-powered antibody discovery platform. Stanley Druckenmiller’s hedge fund owned 659,750 shares of AbCellera Biologics Inc. (NASDAQ:ABCL) in Q1 2022, worth $6.4 million, representing 0.27% of the total 13F holdings. 

AbCellera Biologics Inc. (NASDAQ:ABCL) reported earnings for Q1 on May 10, posting an EPS of $0.54, exceeding analysts’ consensus estimates by $0.12. The revenue grew 56.15% year-over-year to $316.58 million, topping Street forecasts by $96.83 million. 

On May 11, Piper Sandler analyst Do Kim lowered the price target on AbCellera Biologics Inc. (NASDAQ:ABCL) to $21 from $28 and maintained an Overweight rating on the shares. The Q1 beat was due to greater royalty revenue from Lilly-partnered COVID-19 antibody sales, the analyst told investors, but cited increased interest rates and higher beta for the price target drop.

In Q1 2022, Julian Baker and Felix Baker’s Baker Bros. Advisors was one of the leading AbCellera Biologics Inc. (NASDAQ:ABCL) shareholders, with 10.45 million shares worth $101.8 million. Overall, according to Insider Monkey’s data, AbCellera Biologics Inc. (NASDAQ:ABCL) was part of 18 hedge fund portfolios in the fourth quarter of 2021.